Scholarlink

<p>LncRNAs and glycolysis play integral roles in the advancement and development of different types of cancer, such as non-small cell lung cancer (NSCLC). This particular study aims to delve into the specific function and potential mechanism of RP11-544M22.13, a newly identified lncRNA, in NSCLC. We utilized qRT-PCR to measure RP11-544M22.13, miR-1291, and SLC2A1 expression levels. The MTT assay assessed NSCLC cell chemoresistance. RP11-544M22.13 was highly elevated in diamminedichloroplatinum (DDP)-resistant NSCLC tissues and cells, promoting both DDP resistance and malignant behavior. Its mechanism involved targeting SLC2A1, suppressing miR-1291, and subsequently upregulating SLC2A1 expression via direct interaction with SLC2A1 mRNA. RP11-544M22.13 acts as a miR-1291 sponge, boosting SLC2A1 expression and promoting DDP resistance and malignancy in NSCLC cells. This presents a potential treatment target for NSCLC and aids in developing small-molecule drugs for combined chemotherapy in late-stage, chemoresistant NSCLC patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A novel lncRNA RP11-544M22.13 enhances glycolysis-induced cisplatin resistance in non-small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月27日

查看全文
  • Jun Xiong,
  • Haiyue Zhang,
  • Zhou Pan,
  • Yixuan Wang,
  • Hui Chen,
  • Mei Yang

摘要

LncRNAs and glycolysis play integral roles in the advancement and development of different types of cancer, such as non-small cell lung cancer (NSCLC). This particular study aims to delve into the specific function and potential mechanism of RP11-544M22.13, a newly identified lncRNA, in NSCLC. We utilized qRT-PCR to measure RP11-544M22.13, miR-1291, and SLC2A1 expression levels. The MTT assay assessed NSCLC cell chemoresistance. RP11-544M22.13 was highly elevated in diamminedichloroplatinum (DDP)-resistant NSCLC tissues and cells, promoting both DDP resistance and malignant behavior. Its mechanism involved targeting SLC2A1, suppressing miR-1291, and subsequently upregulating SLC2A1 expression via direct interaction with SLC2A1 mRNA. RP11-544M22.13 acts as a miR-1291 sponge, boosting SLC2A1 expression and promoting DDP resistance and malignancy in NSCLC cells. This presents a potential treatment target for NSCLC and aids in developing small-molecule drugs for combined chemotherapy in late-stage, chemoresistant NSCLC patients.